{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ffindmyvaccine.simplecast.com%2Fepisodes%2Frsvpart1-QoB1ZKaa","width":444,"version":"1.0","type":"rich","title":"Antibodies, Vaccines & Baby Season: An RSV Prevention Masterclass with Dr. Zain Chagla","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/749f9235-c5b0-4868-84cf-5a58f2327626/part1zain.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"Episode Description\n\nRSV prevention has entered its “more options, more questions” era. 👶🦠\n\nIn Part 1, infectious disease specialist Dr. Zain Chagla returns to the FindMyVaccine Podcast to help sort through what Canadian clinicians actually need to know about protecting infants from RSV.\n\nFirst up: who is really at risk? Spoiler—the answer is not just premature or medically fragile babies. Dr. Chagla explains why otherwise healthy, full-term infants can still end up hospitalized with RSV, why those first few months of life matter so much, and how to communicate that risk to families without turning counselling into a horror movie.\n\nWe then tackle the updated NACI guidance and the increasingly important choice between maternal vaccination and long-acting monoclonal antibodies. Who should receive what? When does maternal vaccination leave an infant needing additional protection? And which higher-risk babies deserve a particularly proactive plan?\n\nThen comes the immunology—minus the painful lecture.\n\nDr. Chagla explains why monoclonal antibodies are not vaccines, how passive immunization essentially gives infants ready-made RSV-fighting antibodies, and why newer long-acting options have changed the game from repeated injections to protection that can potentially cover much of an RSV season.\n\nAnd because percentages alone rarely tell the whole story, we dig into the evidence: pivotal trials, hospitalization outcomes, absolute risk reduction, high-risk infant data, and why comparing one RSV monoclonal antibody trial directly with another can get scientifically… messy.\n\nBottom line: RSV prevention is no longer simply about knowing that options exist. It is about knowing which option, for which infant, at which time.\n\nClass is officially in session. 🎙️\n\nLearning Objectives\n\nBy the end of this episode, listeners will be able to:\n\nDescribe the clinical burden of RSV in infants and explain why severe disease can occur even in previously healthy, full-term babies.\nInterpret updated Canadian RSV prevention guidance, including the respective roles of maternal vaccination and infant monoclonal antibodies.\nIdentify infants who may warrant a more proactive monoclonal antibody strategy, including those with prematurity, cardiopulmonary disease, immunodeficiency, other medical risk factors, or barriers to timely healthcare access.\nExplain the difference between vaccination and passive immunization, including how long-acting monoclonal antibodies provide immediate protection against RSV.\nTranslate RSV clinical trial results into practical clinical meaning, including relative efficacy, absolute reductions in hospitalization, and important limitations when comparing evidence across trials.\nApply seasonality and local RSV surveillance when considering the timing of infant prevention strategies.\n\n#FindMyVaccine #RSV #RSVPrevention #InfantHealth #MonoclonalAntibodies #MaternalVaccination #PassiveImmunization #NACI #Pediatrics #InfectiousDiseases #VaccineEducation #PublicHealth #CanadianHealthcare\n\nSupported by an IME Grant from Merck\n\n\n\n\n "}